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The aim of this study was to evaluate the eﬃcacy and safety of thrombolytic therapy. Our study enrolled 23 patients out of which
2 patients died due to ICH; we also found that only 39% of patients reached hospital within stroke window, and for those treated,
mean NIHSS during admission was 14.0, but drastic improvement was shown after 24 hours of treatment, that is, 9.89 (P<
0.0001), and at discharge, it was 5.1 (P<0.0001) which showed a clear impact of the treatment, and around 60% of patients were
discharged within an mRS score of 1 and 2. Hence, it was found that thrombolytic therapy was beneﬁcial, eﬃcacious, and safe if
used within 3 to 4.5 hours.
1.Introduction
Cerebrovascular disease usually occurs in the middle and
late stages of life; the incidence of stroke increases with
age; and thus disability occurs to many people in their
“Golden Years.” Some types of the cerebrovascular diseases
include ischemia infarction and intracranial hemorrhage.
Most cerebrovascular diseases are manifest by abrupt onset
of focal neurological deﬁcit. The deﬁcit may remain ﬁxed
or may rapidly improve or progressively worsen. It is this
abrupt onset of nonconvulsive and focal neurological deﬁcit
that deﬁnes stroke, or cerebrovascularaccident. Reduction in
cerebral blood ﬂow causes cerebral ischemia which may last
for seconds to minutes; neurological symptoms can be seen
withinfewsecondsbecauseneuronslackrapidenergyfailure,
and if the blood ﬂow is recovered soon, the symptoms are
only transient and thus termed as transient ischemic attack
(TIA). It becomes very important for a clinician to always
identify, diﬀerentiate, and then treat a stroke; they should
diﬀerentiate ischemia infarction and hemorrhage since their
treatment depends on the cause; the main focus is on two
goals such as to prevent or reverse acute brain injury and to
prevent future neurologic injury [1].
A rapid evaluation is essential for the time-sensitive
treatments such as thrombolysis; there are several other
causes of the sudden onset of neurological symptoms that
may mimic stroke which are seizures, intracranial tumors,
migraine, and metabolic encephalopathy. So we have to
diﬀerentiate all these and then diagnose a stroke; once the
diagnosis is made, a brain imaging study is essential to
ﬁnd the exact cause of the stroke and whether the type of
stroke is ischemic or hemorrhagic. CT imaging becomes the
standard imaging modality to detect the presence or absence
of intracranial hemorrhage. If the stroke is ischemic and the
patient is reaching hospital within a time period of 3 to
4.5 hours, she is a right candidate for thrombolysis using
recombinant tissue plasminogen activator, and then medical
management to reduce the risk of complication becomes the
next priority followed by plans for secondary prevention [2].
An acute occlusion of an intracranial vessel causes reduc-
tion in blood ﬂow in the region it supplies. A fall in cerebral
blood ﬂow to zero causes death of brain tissues within 4
to 10 minutes; values <16 to 18mL/100gm of tissues per
minute cause infarction within an hour, and values less than
20mL/100gm cause ischemia without an infraction unless
prolonged for several hours or days. Tissue surrounding2 ISRN Neurology
the core region of infarction is ischemia but reversibly
dysfunctional and is referred to as ischemic penumbra.
1.1. Treatment of Acute Ischemic Stroke. After the clinical
investigation and diagnosis of stroke is made, it becomes
very necessary to have an orderly process of evaluation, and
treatmentshouldbedone.Theﬁrstgoalshouldbetoprevent
and reverse the brain injury, then attend to his airways,
vitals, and breathing, and treat hyper- or hypoglycemia if
any. We should always perform a noncontrast head CT scan
to rule out any bleed. The treatment mainly falls within
6 categories, namely, medical support, intravenous throm-
bolysis,endovasculartechniques,antithrombotictreatments,
neuroprotection, and stroke centers and rehabilitations [3].
Even after many studies have proven the safety and
eﬃcacy of thrombolytic therapy using Alteplase, very few
centers use this method and treat the patients, and several
reasons explain this situation: a limited therapeutic window,
insuﬃcient public knowledge of warning signs for stroke,
a smaller number of centers available with facilities for the
method, an excessive fear of hemorrhagic complications. In
fact, rt-PA is the only drug licensed for treatment of acute
ischemic stroke [4].
1.2. Thrombolysis and Alteplase. Thrombolysis is mainly
caused by a class of drugs called ﬁbrinolytic drugs, and
this class of drugs break the thrombi by catalyzing the
formation of serine protease plasmin from its precursors
zymogens,plasminogen. Thesedrugscauselysisofclotwhen
administered intravenously. Thus, both protective haemo-
static thrombi and target thromboemboli are broken down.
Plasminogen can also be activated by tissue plasminogen
activator. They activate plasminogen that is bound to ﬁbrin
which causes ﬁbrinolysis of the formed thrombus and ﬁnally
avoids the systemic activation. Human t-PA is manufactured
as Alteplase by means of recombinant DNA technology.
This drug produces its eﬀect by initiating local ﬁbrinolysis
by binding to ﬁbrin in a thrombus (clot) and converts
entrapped plasminogen to plasmin.
1.3. Pharmacodynamics and Pharmacokinetics
1.3.1. Durations. >50% present in plasma is cleared in 5
minutes,andafterinfusionterminated,80%isclearedwithin
10 minutes.
1.3.2. Excretion. Rapidly from circulating plasma (550 to
650mL/min), primarily hepatic, >50% present in plasma
is cleared within 5 minutes, and after the infusion is
terminated, 80% is cleared within 10 minutes.
1.3.3. Dosage. Doses should be given within 3 to 4.5 hours
after the onset of symptoms. Recommended total dose is
0.9mg/kg and maximum dose is 90mg.
1.4. Monitoring Parameters. In acute ischemic stroke, in
addition to monitoring for bleeding complications, the 2007
AHA/ASA guidelines for the early management of acute
ischemic stroke recommend the following:
(1) perform neurological assessment every 15 minutes
during the infusion and every half an hour thereafter
for the next 6 hours then hourly until 24 hours after
the treatment;
(2) if severe headache, nausea, acute hypertension, vom-
iting occur, then discontinue the infusion and do a
CT scan;
(3) monitor BP every 15 minutes for the ﬁrst 2 hours
and then every 30 minutes for the next 6 hours,
then hourly until next 24 hours after the initiation of
Alteplase;
(4) obtain follow-up CT after 24 hours before starting
anticoagulants and antiplatelets.
1.5. Adverse Drug Reaction. Bleeding, hemorrhage, may
occur at any site, reperfusion-related atrial or ventricular
arrhythmia. Some others are hypotension, fever, bruising, GI
bleed, nausea, and vomiting, all these to a lesser extent [5].
Thrombolytic therapy for stroke was reported for the ﬁrst
time in 1958, and then a trial was done in 1963 [6].
1.6. The National Institute of Health Stroke Scale (NIHSS).
We can assess the patient and select the suitable candidates
based on a scale for physical examination; for thrombolytic
therapy, a patient must have more than a minimal neuro-
logical deﬁcit. Patients with only minimal weakness, isolated
ataxia, isolated sensory deﬁcit, or isolated dysarthria are
generallynotcandidatestobethrombolysed.NIHSSisascale
used for neurological examination of the patient showing a
level of consciousness, gaze diﬃculty, facial weakness, limb
weakness, sensory loss, and speech problems. Scores range
from 0 to 42. FDA applies that scores beyond 22 are of a
severe neurological deﬁcit. And patients are more prone to
intracranial hemorrhage if they are administered with rt-PA
after a score of 22. However, patients with NIHSS more than
22 still beneﬁt from the treatment [7].
1.7. Modiﬁed Rankin Scale (mRS). We also have a scoring
system to measure the outcome events of the patients,
for this, we use modiﬁed Rankin scale; it starts with 0
(no disability) and ends with 6 (death), and the primary
measure of outcome is the proportion of patients alive and
independent (mRS 0–2).
Inourhospital,weareperformingthrombolysisforacute
ischemic stroke under the Department of Neurology, using
a drug called Alteplase (a recombinant tissue plasminogen
activator); this subject seemed to be too keen for me to
study its eﬃcacy and to analyze and report on the safety
of this wonder drug, and this made us study Alteplase; if
this treatment is successful and safe, we can also create
awarenessinthecrowdaboutstrokeanditstreatment,within
a thrombolytic time window (3 to 4.5 hours), and we can
generate awareness of the importance of reaching hospital
as soon as possible. Our aim is to report on the safety andISRN Neurology 3
eﬃcacy of the treatment, to what extent the drug is safe to
use, and how eﬀective is the treatment. We have diﬀerent
scalestoassesstheoutcomeofthetherapy;usingthesescales,
we can come to a conclusion about the eﬃcacy of the drug.
2.Methodology
2.1. Study Site. The study was conducted in a private
corporate hospital which has all facilities under one roof.
It is a 700-bedded multispecialty hospital having a wide
range of specialties such as neurology, radiology, nephrology,
urology, oncology, general medicine, diabetology, surgery,
obstetrics, gynecology, cardiology, cardiothoracic surgery,
pulmonology, orthopedics, ophthalmology, dentistry, ENT,
and physical medicine. Neurology and Radiology Depart-
ments of the hospital were particularly chosen for the study,
which has enormous potential for diagnosing and treating
acute ischemic stroke.
2.2. Study Period. T h es t u d yw a sp l a n n e dt ob ec a r r i e do u t
for a period of nine months.
2.3. Study Design: Retrospective and Prospective Study. The
protocol of the study which includes the objectives and
methodology was submitted to the Chairman, KMCRET &
KMCH. The authorization of the Chairman and Medical
Director was obtained to carry out the study.
2.4. Inclusion Criteria. Inpatients with above 18 years of age,
those who were admitted in the hospital for treatment of
acute ischemic stroke and were infused with Alteplase, were
included in this study. Patients with no history of bleed, CT
clearly diagnosing acute ischemic stroke, no recent surgeries,
and onset of symptoms less than 3hrs were included.
2.5. Exclusion Criteria. Patients with unconscious state, NIH
score <4a n d>25, pregnancy, seizure onset, bleeding disor-
ders, and platelet count <100 and patients reaching hospital
after thrombolytic time window period were excluded from
the study.
3. Results andDiscussion
The prospective and retrospective study has shown that the
incidence of the stroke is more common in men than in
women; 95.6 (n = 22) percentage of the men and 4.34
(n = 1) percentage of the women were admitted with stroke
and thrombolysed.
The agewise classiﬁcation revealed that most of the study
population were elderly with the age group between 61 and
80 (n = 11), followed by the age groups 41 to 60 (n =
9 ) ,2 1t o4 0( n = 2), and above 80 (n = 1); no patient
was thrombolysed in the age group between 0 and 20. This
indicates that elderly patients were in need of thrombolytic
therapy.
In this study, 95.6 (n = 22) percentage of the study
populations are married, and 4.34 (n = 1) percentage are
single; this indicates that married people are more prone to
have stroke than unmarried, and this may be due to change
in food habits, life style, stress, and other factors.
This study says that only 7 (34.78%) patients were
smoker and 6 (26.08%) patients were both smoker and
alcoholic.9(39.14%)among23ofthestudypopulationwere
not having any habits of smoking or alcohol. This report is
in contrast with other studies, and this may be due to race,
ethnicity, or any other factors which may concern with the
disease.
The patient’s medical history revealed that 21.73% (n =
5) of the study population had hypertension and 21.73%
(n = 5) had both hypertension and diabetes, which is
followedbycoronaryheartdiseaseandhypertension(8.69%;
n = 2), diabetes alone (8.69%; n = 2), and it is followed by
4.34% (n = 1) each in seizure + hypertension + urinary tract
infection, diabetes and stroke, diabetes and coronary heart
disease, hypertension + stroke, hypertension + diabetes +
stroke, and hypertension + respiratory tract infections. In
this study population, around 13% (n = 3) of the patients
do not have any previous history of disease(s), and they
experienced stroke for the ﬁrst time.
The past medication history of the study population has
shown that nearly 21.73 percent of the study population
received antihypertensive with antidiabetics as past medi-
cation, 17.39 percent received antianginal and antihyper-
tensive, and the same percent of study population did not
receive any drug before getting admission into the hospital.
13.04 percent received antihypertensive as monotherapy,
and the same percent received the antihypertensive with
lipid-lowering agents as combination therapy. Only the
least number (n = 1) of patients received antidiabetics
and antianginal and antihypertensive + antiepileptics +
antibiotics as combination therapy. This data revealed that
most of thestudy population werediabetic and hypertensive,
which are the risk factors for stroke (Table 1).
In this study population, the left middle cerebral arteries
were aﬀected more in around 60.86% of the study pop-
ulation, and right middle cerebral arteries were aﬀected
in around 13.04% of patients; both intracranial artery
and middle cerebral arteries were aﬀected in 8.6%, and
intracranial artery alone was aﬀected in 8.6%; intracranial
artery,middlecerebralartery,andoccipitallobewereaﬀected
in 4.3%, and basilar artery was aﬀected in 4.3% of the study
population. This revealed that most of the patients who
h a ds t r o k ew e r ea ﬀected with left middle cerebral arteries
(Table 2).
The past history of stroke concluded that 83 percentage
of the study population previously had stroke, and only 17
percent had the stroke for the ﬁrst time. This indicates that
the stroke patients are more prone to have recurrent attack
and alarms the physician and patients regard the severity and
the need of eﬀective treatment.
All the study population were thrombolysed. Among the
23 of the study population, 2 died with intracerebral hem-
orrhage, which is an associated risk with the thrombolytic
therapy, and when compared to other studies mentioned
in our study, it is less. It says that the use of thrombolytic
therapy (Alteplase) was safe, and the rate of intracerebral
hemorrhage was low (Figure 1).4 ISRN Neurology
Table 1: Past medication history of the study population.
Drugs Number of
patients
Percentage
(%)
Antidiabetics 2 8.69
Antihypertensives 3 13.04
Antihypertensives +
lipid-lowering therapy 3 13.04
Antianginal + antihypertensives 4 17.39
Antihypertensives + antidiabetics 5 21.73
Antidiabetics + antianginal 1 4.34
Antihypertensives +
antiepileptics + antibiotics 14 . 3 4
Nil 4 17.39
Table 2: Area of the brain aﬀected in study population.
Area aﬀected Number
of patients
Percentage
(%)
Right middle cerebral arteries (Rt MCAs) 3 13.04
Left middle cerebral arteries (Lt MCAs) 14 60.86
Basilar artery 1 4.3
Intracranial artery 2 8.6
Intracranial artery + middle cerebral
arteries 28 . 6
Intracranial artery + middle cerebral
arteries + occipital lobe 14 . 3
All the study population were treated with the throm-
bolytic Alteplase (rtPA); clopidogrel and aspirin combina-
tion was prescribed for all the study population; neuropro-
tectives were prescribed for around 87% of the patients,
which is followed by lipid-lowering agents and antiepileptics
(78.26); anxiolytics was the least prescribed drug in the
study population. Proton pump inhibitors were commonly
prescribed in 87% of the study population (Figure 2).
Around 39 percent of the study population reached the
hospital within 3 hours after the onset of symptoms, and
nearly 22% reached between 3 and 4 hours. 13% of the
patients reached the hospital within 4 to 5 hours. No patient
was found in the time period of above 5 hours, but around
26 percent of patients were not aware of the time of onset of
symptoms (Table 3).
The current study revealed that around 61 percentage of
the study population were injected the drug Alteplase within
31 to 60 minutes after getting admission to the hospital. The
drug was injected initially to thrombolyse the clot and to
give speedy recovery to the patient. 22 percent received the
treatmentwithin61to90minutes;onlyfewpatientsreceived
the treatment after 90 minutes; it indicates that the early
treatment with Alteplase is required in most of the patients.
None of the study population received the drug immediately
once they get in to the hospital or after admission, because
the time lag may be used for the initial investigation and
diagnosis of the disease (Table 4).
The National Institute of Health Stroke Scale (NIHSS)
scores revealed that most of the patients scored high values
8.69%
91.3%
Mortality rate
survived of patients No.
Figure 1: Rate of successful thrombolysis.
Table 3: Time to reach hospital in the study population.
Time to reach % of patients
0–3hr 39.13%
>3-4hr 21.73%
>4-5hr 13.04%
>5hr 0%
Not aware 26.08%
with the mean of 14.0 when they were admitted in the
hospital with a number of disabilities and severities, but after
24 hours, the score was signiﬁcantly reduced to a mean value
of 9.89. This happened because of the eﬀective treatment
with the recombinant tissue plasminogen activator (rtPA)
ALTEPLASE. A reduction in 4 or more scores after 24 hours
clearly shows the eﬀect of drug. This drug was more eﬀective
in breaking the clot and allowing the cerebral perfusion. And
there was a signiﬁcant diﬀerence in the treatment (Table 5).
The National Institute of Health Stroke Scale (NIHSS)
scores revealed that most of the patients scored high values
with the mean of 14.0 when they were admitted in the
hospitalwithanumberofdisabilitiesandseverities,butlater,
that is, at the time of discharge, the score was remarkably
reduced to a mean valueof 5.1. This happened becauseof the
eﬀective treatment with the recombinant tissue plasminogen
activator (rtPA) ALTEPLASE. This drug was more eﬀective
in breaking the clot and allowing the cerebral perfusion. And
there is a signiﬁcant diﬀerence in the treatment (Table 6).
mRS score is an outcome score used to predict the
outcome of the treatment; the least score is an indicative
of good outcome, and higher score is an indicative of poor
outcome. In this study, the majority of the patients scored
1 and 2 in mRS scale which indicates that the outcome of
the treatment is beneﬁcial and eﬀective. Most of the patients
were discharged with very fewer disabilities. In this study
population, 2 patients died with the MRS scale score of 6,
because of poor recovery (Table 7).
4. Conclusion
In this study, most of the patients were male and only one
patient was female, which indicates that this stroke problemISRN Neurology 5
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Figure 2: Present medication histories of the patients.
Table 4: Door to needle time in study population.
Door to needle time % of patients
0–30min 0.00%
31–60min 60.86%
61–90min 21.73%
>90min 4.86%
Not aware 13.04%
Table 5: Mean NIHSS of study population after 24 hours.
Nih stroke score Mean value P value
Before score 14.0 <0.0001
After score 9.89
Table 6: Mean NIHSS of the patient at the time of discharge.
Nih stroke score Mean value P value
Before socre 14.0 <0.0001
After score 5.1
Table 7: Outcome scores of mRS in percentage.
m R S s c o r e 012 3 4 5 6
%o f
Patients 13.04% 34.78% 30.43% 8.6% 4.86% 0% 8.6%
is more common in male than in female in this locality, but
we cannot conclude that thrombolysis is more eﬃcient in
male,asitisstudiedandconcludedthatthereisnodiﬀerence
in the outcome of thrombolysis based on gender [8]. Nearly
half of the study population were elderly, which reveals that
stroke is mostly aﬀecting the elderly patients; this may be
due to several physiological and behavioral reasons; we have
also thrombolysed a patient who was above 80 years of age
based on the beneﬁt over risk ratio and a study supporting
this which concluded that there was a better outcome in
patients who were thrombolysed than those who were not
thrombolysed; our study comprised of a patient aged more
than 80 who was discharged with a desired outcome score
[9].
We also found that around 95% of the study population
were married. According to this study, smoker alcoholics
are having less chance of getting stroke than those not
having any type of such habit; in this aspect, our study is
more in contrast to various other studies which say that
smoking and alcoholism are the major risk factors for stroke.
Hypertension and diabetes were the most common diseases
weobservedinthisstudypopulationaspatient’spastmedical
history; the combination of these diseases in any patient
increases the chance of getting stroke, and they are treated
with same class of drugs.
Middle cerebral arteries (MCAs) were mostly aﬀected by
stroke, more predominantly left middle cerebral arteries (LT
MCA) in the study population than other parts of the brain;
this may be due to the degenerative disease of the arteries of
brainandhighbloodpressure.Notonlyinourstudy,butalso
this is common in many other studies like STARS (standard
treatmentwithAlteplasetoreversestroke)[10].Inthisstudy,
a large number of patients who were thrombolysed were
aﬀectedbymiddlecerebralarteries,morepredominantlyleft,
which was similar to our study.
Alteplaseiscommonlyprescribedtothrombolysetheclot
for all the patients in our study. Alteplase can also induce
intracerebral hemorrhage (ICH), but in our study, only few
patients had intracerebral hemorrhage and 2 died due to the
same problem; this reveals the safety of the therapy, and this6 ISRN Neurology
was proven by many studies, one of which is CASES [11];
this study concluded that the rate of ICH is low and use of
thrombolytic therapy is safe in actual practice. Most of the
patients do not have any bleeding complaint. So this study
concludes that Alteplase is safe for the treatment of stroke.
83 percent of the ages of patients having the previous
history of stroke, and now they have admitted in our hospital
for the treatment, indicates that the stroke is repeatedly
aﬀecting the population and they are in need of proper,
safer, and reliable treatment with suitable drugs. Apart from
Alteplase, antiplatelets aggregating agents were commonly
prescribed in our study population; almost all the patients
received the clopidogrel and aspirin combination to lyse the
thrombus.
The speed of recovery depends on the arrival of the
patients to the hospital after getting the onset of symptoms.
Nearly one-third of the patients got admission into the
hospital within 3 hours, which is very essential for saving the
life of the victim.
Most important is the time for the treatment, and many
studies proved that the use of the drug within 3 hours after
the stroke symptoms can be very result oriented and safe,
a study called (SITS-MOST) [12]; they too concluded that
intravenous Alteplase is safe and eﬀective in clinical routine
within 3 hours of the symptoms. Drug Alteplase was injected
to the patients after 30 minutes of getting admission into this
hospital;nearly60percentreceivedthedruginthesametime
period which indicates that the ﬁrst few minutes were taken
to diagnose and investigate the problem.
Our study too came up with a conclusion that throm-
bolytic therapy is eﬃcacious based on the outcome scores
of NIHSS and mRS; our treatment is signiﬁcant with an
NIHSS mean value of prevalue and postvalue after both 24
hours and even during discharge and the mean values of
thrombolysis after 24 hours (before 14.0 and after 9.89) were
highly signiﬁcant; a mean discharge score was also obtained
(before 14.0 and after 5.1); there were drastic improvements
in the scores, and treatment was beneﬁcial as it was studied
in STARS [10].
Modiﬁed Rankin scale was used to conclude the outcome
of the therapy; in our study, we discharged the majority
of patients with a score of 0 to 2 which was an expected
favorable outcome score to be discharged, and this was
similar to CASES [13].
The total sum of the thesis reveals that the use of
ALTEPLASE in an acute ischemic stroke is safe and eﬃ-
cacious within a thrombolytic window of 3 to 4.5 hours,
p r o v i d e di ts h o u l db ed o n ei ns e l e c t e dp o p u l a t i o nw i t h i na
well-ﬂourished hospital and well-trained hands with skilled
medical teams.
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